PharmaShots Interview: Genentech’s Dr. Neil Collinson Shares Insights on Xofluza

In a recent interview with PharmaShots, Dr. Neil Collinson, the Senior Principal Clinical Development Scientist at Genentech / Roche shares his insights and highlights on Xofluza.Shots:The P-III BLOCKSTONE study demonstrated that the proportion of household members who became symptomatically ill following infection with influenza was significantly lower in those treated preventively with Xofluza…

BySenior EditorSeptember 22, 2020

VIEWPOINTS

PharmaShots Interview: Genentech’s Ted Omachi Shares Insights on Xolair (omalizumab) PFS

The US FDA has accepted the sBLA for a new self-administration option for Xolair (omalizumab) across all approved US indications.In an interview with PharmaShots, Ted Omachi the Global Development Leader for Xolair and Senior Medical Director of Product Development Immunology shares details and highlights of Xolair (omalizumab) PFS for self-administration.Shots:A decision on…

BySenior EditorSeptember 7, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of August 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyMylan with its partner Lupin and Biocon launched Nepexto (biosimilar, etanercept) and Semglee (insulin glargine injection) in Germany & in the US, respectively. Additionally, Formycon and Bioeq planned to initiate P-III MAGELLAN-AMD Trial for its FYB203 (biosimilar,…

BySenior EditorSeptember 3, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in July 2020

The US FDA has approved multiple NDAs and BLAs in July 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 59 novel products so far in 2020, including 8 in July 2020. Additionally,…

BySenior EditorAugust 27, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of July 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyCadila expanded its footprints in India with the launch of its two biosimilars Bevaro (bevacizumab, biosimilar) and Ritucad (rituximab, biosimilar)Our team at PharmaShots has summarized 9 key events of the biosimilar space of July 20201. Samsung…

BySenior EditorAugust 7, 2020

VIEWPOINTS

PharmaShots Interview: Paige’s CEO, Leo Grady Shares Insights on its Series B Funding and the FDA’s 510(k) Clearance for FullFocus Viewer

Paige is a global digital pathology founded in 2017 by Thomas Fuchs, Dr. Sc., and colleagues from Memorial Sloan Kettering Cancer Center. The company involves computational pathology products that are targeted for patients and their care teams for effective, more informed treatment decisions. Paige has developed a platform to deliver novel technology to pathologists to…

BySenior EditorJuly 17, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of June 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyMylan with its partners Lupin and Biocon received MAA for Nepexto (biosimilar, etanercept) in EU and the US FDA's Approval for Semglee (biosimilar, insulin glargine) respectivelyOur team at PharmaShots has summarized 15 key events of the…

BySenior EditorJuly 3, 2020

EVENTS

Exclusive Webinar: Strategies to Conduct Clinical Trials Effectively in Covid-19 Era

The Webinar on 'Strategies to Conduct Clinical Trials effectively in Covid-19 era' organized by CliniMed LifeSciences Pvt. Ltd., Kolkata in association with Indian Society for Clinical Research (ISCR) and Peerless Hospital, Kolkata as knowledge partners and PharmaShots as a media partner, was held at 3 pm on June 6, 2020. Around 500 plus participants attended…

BySenior EditorJune 18, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in March and April 2020

The US FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 48 new products so far in 2019.However, there is a significant increase in multiple diseases while the new approvals are helping and advancing the changes to understand, diagnose, and treat the diseasesOur team…

BySenior EditorMay 15, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of April 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a 'reference…

BySenior EditorMay 8, 2020

PharmaShots Interview: Genentech’s Dr. Neil Collinson Shares Insights on Xofluza

PharmaShots Interview: Genentech’s Ted Omachi Shares Insights on Xolair (omalizumab) PFS

Insights+ Key Biosimilars Events of August 2020

Insights+: The US FDA New Drug Approvals in July 2020

Insights+ Key Biosimilars Events of July 2020

PharmaShots Interview: Paige’s CEO, Leo Grady Shares Insights on its Series B Funding and the FDA’s 510(k) Clearance for FullFocus Viewer

Insights+ Key Biosimilars Events of June 2020

Exclusive Webinar: Strategies to Conduct Clinical Trials Effectively in Covid-19 Era

Insights+: The US FDA New Drug Approvals in March and April 2020

Insights+ Key Biosimilars Events of April 2020

Contact US

OUR INFORMATION

FOLLW US

FOLLW US

Sign Up to Our Newsletter